New drug could replace current standard for treating brain cancer
Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation…
January 20, 2023 - 3 minutes
Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation…
Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A,…
Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies,…
Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively…
The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme…